Physician profile
Gyan Brard
NPI 1154397750
$11,714.15
in general payments reported to CMS, 2019-2025
55 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,407 · 2020: $1,436 · 2021: $1,555 · 2022: $1,567 · 2023: $1,793 · 2024: $1,472 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Education: $31.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.82 |
| Education | $31.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,557.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,383.46 | 2019-2025 | |
| Abbott Laboratories | $971.47 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.17 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $627.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $607.87 | 2019-2021 | |
| Dexcom, INC. | $563.51 | 2020-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $494.33 | 2019-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $425.26 | 2019-2025 | Korlym |
| Insulet Corporation | $383.81 | 2019-2025 | Omnipod |
| Mannkind Corporation | $346.71 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $242.11 | 2020-2024 | Gvoke Hypopen |
| Medtronic, INC. | $229.80 | 2023-2025 | Minimed 780g |
| Lifescan, INC. | $226.35 | 2019-2020 | |
| Antares Pharma, INC. | $220.42 | 2019-2023 | Tlando, Xyosted, Nocdurna |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $207.78 | 2019-2023 | Unithroid |
| Radius Health, INC. | $207.71 | 2019-2023 | Tymlos |
| Abbvie INC. | $201.81 | 2019-2024 | Synthroid, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $195.28 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $194.08 | 2023-2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $146.30 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $115.18 | 2023-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $113.75 | 2019-2025 | Tirosint, Flector, Licart |
| Beta Bionics, INC. | $111.55 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Pfizer INC. | $105.43 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $104.91 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $86.65 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $79.11 | 2023 | Cequr Simplicity |
| Sequel Med Tech, LLC | $76.78 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $75.17 | 2019-2021 | |
| Clarus Therapeutics INC. | $67.70 | 2021 | |
| Intuity Medical INC | $58.46 | 2022 | |
| Embecta Corp. | $55.15 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Becton, Dickinson and Company | $55.04 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $48.90 | 2021 | |
| Amarin Pharma, INC. | $40.85 | 2020-2021 | |
| Gilead Sciences, INC. | $26.90 | 2019 | |
| Biogen, INC. | $25.98 | 2025 | Skyclarys |
| Alvogen INC | $25.93 | 2022 | |
| Companion Medical, INC. | $25.41 | 2020 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Verity Pharmaceuticals INC. | $23.50 | 2024 | Tlando |
| Averitas Pharma INC. | $22.82 | 2023 | Qutenza |
| Ascensia Diabetes Care US INC. | $22.35 | 2023 | |
| Senseonics, Incorporated | $21.00 | 2019 | |
| Kyowa Kirin, INC. | $20.95 | 2023 | Crysvita |
| Renalytix Ai, INC. | $20.69 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Zealand Pharma US, INC. | $19.33 | 2021 | |
| Horizon Therapeutics Plc | $19.00 | 2022 | |
| Exelixis INC. | $19.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.32 | 2023 | Strensiq |
| Astellas Pharma US INC | $17.88 | 2024 | Veozah |
| Tolmar, INC. | $17.18 | 2024 | |
| Echosens North America, INC. | $15.70 | 2025 | Fibroscan |
| Shire North American Group INC | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gyan Brard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.